- Home
- SBGI vs CVAC Comparison
SBGI vs CVAC Comparison
Compare SBGI & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBGI
- CVAC
- Stock Information
- Founded
- SBGI 1986
- CVAC 2000
- Country
- SBGI United States
- CVAC Germany
- Employees
- SBGI N/A
- CVAC N/A
- Industry
- SBGI Broadcasting
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- SBGI Industrials
- CVAC Health Care
- Exchange
- SBGI Nasdaq
- CVAC Nasdaq
- Market Cap
- SBGI 1.1B
- CVAC 1.2B
- IPO Year
- SBGI 1995
- CVAC 2020
- Fundamental
- Price
- SBGI $14.46
- CVAC $5.39
- Analyst Decision
- SBGI Buy
- CVAC Hold
- Analyst Count
- SBGI 5
- CVAC 3
- Target Price
- SBGI $18.50
- CVAC $6.83
- AVG Volume (30 Days)
- SBGI 365.9K
- CVAC 854.9K
- Earning Date
- SBGI 08-06-2025
- CVAC 08-14-2025
- Dividend Yield
- SBGI 7.05%
- CVAC N/A
- EPS Growth
- SBGI N/A
- CVAC N/A
- EPS
- SBGI 1.97
- CVAC 0.87
- Revenue
- SBGI $3,526,000,000.00
- CVAC $566,039,775.00
- Revenue This Year
- SBGI N/A
- CVAC N/A
- Revenue Next Year
- SBGI $9.59
- CVAC $24.04
- P/E Ratio
- SBGI $7.21
- CVAC $6.23
- Revenue Growth
- SBGI 11.62
- CVAC 787.60
- 52 Week Low
- SBGI $12.07
- CVAC $2.37
- 52 Week High
- SBGI $18.46
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- SBGI 48.46
- CVAC 55.44
- Support Level
- SBGI $14.66
- CVAC $5.38
- Resistance Level
- SBGI $15.69
- CVAC $5.48
- Average True Range (ATR)
- SBGI 0.55
- CVAC 0.06
- MACD
- SBGI -0.11
- CVAC -0.04
- Stochastic Oscillator
- SBGI 25.90
- CVAC 28.57
About SBGI Sinclair Inc.
Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay-TV distributors.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.